Research Papers:
Claudin3 is localized outside the tight junctions in human carcinomas
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2278 views | HTML 2505 views | ?
Abstract
Michela Corsini1, Antonella Ravaggi2, Franco Odicino2, Alessandro Davide Santin3, Cosetta Ravelli1,4, Marco Presta1, Chiara Romani2,* and Stefania Mitola1,4,*
1Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
2Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, 'Angelo Nocivelli' Institute of Molecular Medicine, University of Brescia, Brescia, Italy
3Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT, USA
4Department of Molecular and Translational Medicine, Laboratory for Preventive e Personalized Medicine, University of Brescia, Brescia, Italy
*These authors have contributed equally to this work
Correspondence to:
Chiara Romani, email: [email protected]
Stefania Mitola, email: [email protected]
Keywords: claudin3; tight junction; ovarian cancer; uterine cancer
Received: October 05, 2017 Accepted: March 06, 2018 Published: April 06, 2018
ABSTRACT
Claudin3 is an integral component of the tight junction proteins in polarized epithelia. The expression of claudin3 was assessed in epithelial-derived tumors using Oncomine database. To determine the gene alteration during carcinogenesis, copy number alterations and mutations of claudin3 were evaluated using cBioPortal database. Claudin3 is overexpressed in several tumors including gynecological, bladder, breast and prostate carcinomas. 38% of the 163 evaluated studies show mutations and/or amplification of claudin3. 3D reconstruction of tissue samples following immunofluorescence analysis clearly demonstrated that, unlike in healthy tissues, claudin3 is mislocalized and unengaged in the formation of tight junction in tumor samples. These data strongly support the evaluation of unengaged claudin3 as a target for the development of novel diagnostic probes, optical approaches for real time detection of tumoral tissues during surgery, and target therapeutic drugs.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24858